SEC Form 4 · accession 0000899243-18-013577
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rodger Novak
Officer — President · Director
Period of report
May 17, 2018
Accepted (ET)
May 21, 2018 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | May 17, 2018 | M | 35,240 | $1.81 | A | 1,183,247 | D | |
| Common Shares | May 17, 2018 | M | 39,760 | $14.00 | A | 1,223,007 | D | |
| Common Shares | May 17, 2018 | S | 75,000 | $60.00 | D | 1,148,007 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.81 | May 17, 2018 | M | 35,240 | D | — | Sep 10, 2025 | Common Stock | 35,240 | 5,586 | D |
| Stock Option (Right to Buy)F3 | $14.00 | May 17, 2018 | M | 39,760 | D | — | Oct 18, 2016 | Common Stock | 39,760 | 160,240 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31equal monthly installments thereafter.
- F3This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.